Clinical use of approved influenza antivirals: Therapy and prophylaxis

Influenza and other Respiratory Viruses

Volumn 7, Issue 1 SUPPL.1, 2013, Pages 7-13

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adamantanes; Antiviral agents; Influenza; M2 inhibitors; Neuraminidase inhibitors

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; CS 08958; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

AGITATION; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTICLE; ATAXIA; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; CYSTITIS; DELIRIUM; DELUSION; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HALLUCINATION; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA A; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; INSOMNIA; IRRITABILITY; MEMORY DISORDER; MOOD CHANGE; NAUSEA; NERVOUSNESS; NEUTROPHIL COUNT; NIGHTMARE; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; SINGLE DRUG DOSE; SLURRED SPEECH; SOMNOLENCE; TREMOR; VISUAL DISORDER; VOMITING;

ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; NEURAMINIDASE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84871824506     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12046     Document Type: Article

References (54)

1. Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol 2001; 1:482-490.
2. Hayden FG, Aoki FY. Amantadine, rimantadine, and related agents. in Yu VL, Marigan TCJ, Barriere SL (eds): Antimicrobial Therapy and Vaccines. Baltimore, MD: Williams & Wilkins, 1999; 1344-1365.
3. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-1181.
4. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
5. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews 2006; Issue 2. Art. No.: CD001169. DOI: 10.1002/14651858.CD001169.pub3.
6. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011; 1:563-573.
7. Bryson YJ. The use of amantadine in children for prophylaxis and treatment of influenza A infections. Pediatr Infect Dis 1982; 1:44-46.
8. Thompson J, Fleet W, Lawrence E, Pierce E, Morris L, Wright P. A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Virol 1987; 21:249-255.
9. Deyde VM, Nguyen T, Bright RA et al. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Antimicrob Agents Chemother 2009; 53:1039-1047.
10. Colman PM. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 1994; 3:1687-1696.
11. Yamashita M. Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza. Antiviral Chem Chemother 2010; 21:71-84.
12. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial. Clin Infect Dis 2010; 51:1167-1175.
13. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010; 54:2575-2582.
14. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
15. Bantia S, Parker CD, Ananth SL et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001; 45:1162-1167.
16. Sugaya N, Mitamura K, Yamazaki M et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44:197-202.
17. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-1672.
18. Boltz DA, Aldridge Jr. Jr, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70:1349-1362.
19. Whitley RJ, Hayden FG, Reisinger KS et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001; 20:127-133.
20. Chairat K, Tarning J, White NJ, Lindegardh N. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol 2012; Epub Ahead of Print.
21. Kaiser L, Keene ON, Hammond JM, Elliott M, Hayden FG. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160:3234-3240.
22. Prevention CfDCa. Emergency Use Authorization of Peramivir IV: Fact Sheet for Health Care Providers. In., 2009.
23. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010; 54:4568-4574.
24. Kohno S, Yen MY, Cheong HJ et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267-5276.
25. Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.
26. Ison MG, Gnann JW Jr, Nagy-Agren S et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003; 8:183-190.
27. Duval X, van der Werf S, Blanchon T et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
28. Ison MG, de Jong MD, Gilligan KJ et al. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis 2010; 201:1654-1662.
29. Lee N, Ison MG. Diagnosis, management and outcomes of adults hospitalized with influenza. Antivir Ther 2012; 17(1 Pt B):143-157.
30. Bautista E, Chotpitayasunondh T, Gao Z et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362:1708-1719.
31. Ison MG, Lee N. Influenza 2010-2011: lessons from the 2009 pandemic. Clevel Clin J Med 2010; 77:812-820.
32. Ison MG. Epidemiology, prevention, and management of influenza in patients with hematologic malignancy. Infect Disord Drug Targets 2011; 11:34-39.
33. Khanna N, Steffen I, Studt JD et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11:100-105.
34. Ison MG, Hirsch HH. Influenza: a recurrent challenge to transplantation. Transpl Infect Dis 2010; 12:95-97.
35. Baluch A, Humar A, Egli A et al. Long term immune responses to pandemic influenza A/H1N1 infection in solid organ transplant recipients. PLoS ONE 2011; 6:e28627.
36. Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11:2020-2030.
37. Ljungman P, Cordonnier C, Einsele H et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44:521-526.
38. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10:521-526.
39. Ljungman P, de la Camara R, Perez-Bercoff L et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96:1231-1235.
40. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant 2008; 27:282-288.
41. Ng BJ, Glanville AR, Snell G et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11:568-574.
42. Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf 2010; 33:631-642.
43. Greer LG, Leff RD, Rogers VL et al. Pharmacokinetics of oseltamivir in breast milk and maternal plasma. Am J Obstet Gynecol 2011; 204:524-e521.
44. Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008; 2008:927574.
45. Beigi RH, Han K, Venkataramanan R et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 2011; 204(6 Suppl 1):S84-S88.
46. Cervantes-Gonzalez M, Launay O. Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment. Expert Rev Anti Infect Ther 2010; 8:981-984.
47. Greer LG, Sheffield JS, Rogers VL, Roberts SW, McIntire DD, Wendel GD Jr. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. Obstet Gynecol 2010; 115:711-716.
48. Siston AM, Rasmussen SA, Honein MA et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303:1517-1525.
49. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women. CMAJ 2009; 181:55-58.
50. Greer LG, Leff RD, Rogers VL et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204(6 Suppl 1):S89-S93.
51. Adisasmito W, Chan PK, Lee N et al. Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1). J Infect Dis 2011; 204:810-811.
52. Beigel JH, Farrar J, Han AM et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353:1374-1385.
53. de Jong MD, Bach VC, Phan TQ et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352:686-691.
54. de Jong MD, Tran TT, Truong HK et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005; 353:2667-2672.